{"id":708158,"date":"2026-06-16T20:54:08","date_gmt":"2026-06-16T20:54:08","guid":{"rendered":"https:\/\/www.newsbeep.com\/us\/708158\/"},"modified":"2026-06-16T20:54:08","modified_gmt":"2026-06-16T20:54:08","slug":"syremis-therapeutics-adds-aaron-koenig-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us\/708158\/","title":{"rendered":"Syremis Therapeutics Adds Aaron Koenig as Chief Medical Officer"},"content":{"rendered":"<p class=\"has-background\" style=\"background-color:#bebebe\">Why This Matters: See our coverage of other industry executive team appointments and promotions <a href=\"https:\/\/www.contractpharma.com\/breaking-news\/?sticky=promotions-moves\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>.<\/p>\n<p><a href=\"https:\/\/syremis.com\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Syremis Therapeutics<\/a>, a clinical-stage biopharmaceutical company developing novel medicines for mental health disorders, appointed Aaron Koenig, MD, Chief Medical Officer.<\/p>\n<p>Koenig, a psychiatrist by trade, is recognized as a drug development leader whose experience includes neuropsychiatric disorders and neurodegenerative diseases. Namely and notably, this area of expertise encompasses Alzheimer\u2019s disease.<\/p>\n<p>Chief Medical Officer Experience<\/p>\n<p>Prior to his appointment at Syremis, Koenig held the same Chief Medical Officer post at Syndeio Biosciences and Delix Therapeutics. At Delix, he oversaw development of a range of novel neuropsychiatric drug candidates, according to information provided by Syremis.<\/p>\n<p>Previously, Koenig led multiple neuropsychiatry programs at Sage Therapeutics, where he had held numerous leadership roles. Among the programs Koenig oversaw at Sage were candidates for treatment of cognitive impairment associated with neurodegenerative disease.<\/p>\n<p>Earlier in his career, Koenig worked as a clinical investigator for the Massachusetts Alzheimer\u2019s Disease Research Center.<\/p>\n<p>Syremis Welcomes New Team Member<\/p>\n<p>\u201cI am excited to join Syremis at such a pivotal time,\u201d Koenig said. \u201cI know firsthand how far the current standard of care falls short for patients with schizophrenia and depression. The science underpinning Syremis\u2019 pipeline gives me confidence that we can make meaningful progress and help address significant unmet needs.\u201d<\/p>\n<p>\u201cAaron\u2019s unique combination of frontline clinical experience and neuropsychiatric drug development expertise strengthens Syremis,\u201d Co-Founder and CEO Elisabeth Kogan said. \u201cHis understanding of patient need and how to prove clinical impact is exactly the perspective [to] drive our programs forward.\u201d<\/p>\n<p>Syremis\u2019 lead program, ST-905, is a dual M1\/M4 agonist currently in Phase I development for schizophrenia, among other conditions.<\/p>\n","protected":false},"excerpt":{"rendered":"Why This Matters: See our coverage of other industry executive team appointments and promotions here. Syremis Therapeutics, a&hellip;\n","protected":false},"author":2,"featured_media":708159,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-708158","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/708158","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=708158"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/708158\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/708159"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=708158"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=708158"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=708158"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}